

**Oklahoma Health Care Authority  
Drug Utilization Review Board  
(DUR Board)**

**Meeting – December 11, 2013 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

**1. Call To Order**

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

**2. Public Comment Forum**

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

**3. Action Item - Approval of DUR Board Meeting Minutes – See Appendix A**

- A. November 13, 2013 DUR Minutes – Vote
- B. November 13, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Nesser, Dr. Muchmore, Chairman:

**4. Announcement Regarding DUR Board Meeting Time and Location - See Appendix B**

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**5. Action Item – Update on Medication Coverage Authorization Unit, RetroDUR, and Vote to Prior Authorize Ketoconazole Oral Tablets – See Appendix C**

- A. Medication Coverage Activity Report for November 2013
- B. Pharmacy Help Desk Activity Report for November 2013
- C. Retrospective Drug Utilization Review Report for July, August, and September
- D. Vote to Prior Authorize Ketoconazole Oral Tablets

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Update the Antihypertensive Product Based Prior Authorization Category and Prior Authorize Epaned™ – See Appendix D**

- A. COP Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Zetonna® – See Appendix E**

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**8. Action Item - Vote to Prior Authorize Rescula® and Simbrinza™ – See Appendix F**

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

- 9. Action Item - Vote to Prior Authorize Sklice<sup>®</sup> – See Appendix G**  
A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

- 10. Fiscal Year 2013 Annual Review of Advair<sup>®</sup>, Symbicort<sup>®</sup>, Dulera<sup>®</sup>, and 30 Day Notice to Prior Authorize Breo<sup>™</sup> Ellipta<sup>™</sup> – See Appendix H**  
A. Current Prior Authorization Criteria  
B. Prior Authorization Review  
C. Market News and Updates  
D. Product Summary  
E. COP Recommendations  
F. Utilization Details  
G. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

- 12. FDA and DEA Updates – See Appendix I**

- 13. Future Business**

- 14. Adjournment to Proposed Executive Session as Recommended by the General Counsel and Authorized by the Open Meetings Act, Okla. State. § 307 (8) (4), (7).**  
The Executive Session will take place at Iron Starr, 3700 N. Shartel, Oklahoma City, OK 73118.